HomeAI · summaries
Storia in 7 fonti
Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why - Crinetics Pharmaceuticals (NASDAQ:C
Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
markets.businessinsider.com
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceut...
- ·
endpoints.news
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.
